ARTICLE | Clinical News
PRO 206: Development discontinued
June 15, 2009 7:00 AM UTC
Progenics discontinued development of PRO 206, which was in preclinical development, in order to focus its resources on its second-generation HCV-entry inhibitor portfolio. The company expects to sele...